IMR Press / FBL / Volume 7 / Issue 4 / DOI: 10.2741/anderson

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
ErbB receptor tyrosine kinase inhibitors as therapeutic agents
Show Less
1 Division of Cancer Studies, School of Medicine, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom
Front. Biosci. (Landmark Ed) 2002, 7(4), 1926–1940; https://doi.org/10.2741/anderson
Published: 1 September 2002
Abstract

The ErbB family of receptor tyrosine kinases comprise four members: EGFR, ErbB2, ErbB3 and ErbB4. All are essential for normal development and participate in the functioning of normal cells. ErbB receptors, particularly EGFR and ErbB2 are commonly deregulated in certain prevalent forms of human cancer. Recently a number of small molecule inhibitors of the tyrosine kinase activity of these receptors have been developed. Some of these agents, known as TKIs, are progressing through clinical trials in patients with aberrant ErbB receptor expression in their tumors. This article provides a brief overview on the structure and biology of ErbB receptors and their ligands before discussing in detail the development and current status of ErbB receptor TKIs. These agents are shown to inhibit multiple features of cancer cells including proliferation, survival, invasion and angiogenesis. It is clear from recent studies that not all cancer cells that overexpress ErbB receptors will be sensitive to TKIs. Potential explanations for resistance to these molecules are reviewed. Finally the prospect of using TKIs in combination with existing chemotherapeutic agents is discussed.

Keywords
EGF
EGFR
ErbB-2
cancer
TKI
signal transduction inhibitor
Review
Share
Back to top